دورية أكاديمية
أعرض في EDS

The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status: A Study By the International Genetic Consortium for Colorectal Liver Metastasis.

التفاصيل البيبلوغرافية
العنوان: The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status: A Study By the International Genetic Consortium for Colorectal Liver Metastasis.
المؤلفون: Margonis GA; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland., Amini N; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland., Buettner S; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland., Kim Y; Department of Population Medicine, Harvard Pilgrim Health Care Institute and the Department of Dermatology, Massachusetts General Hospital, Boston: Massachusetts., Wang J; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland., Andreatos N; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland., Wagner D; Department of General Surgery, Medical University of Graz, Graz, Austria., Sasaki K; Department of General Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio., Beer A; Department of General Surgery, Medical University of Vienna, Vienna, Austria., Kamphues C; Department of General, Visceral and Vascular Surgery, Charite Campus Benjamin Franklin, Berlin, Germany., Morioka D; Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan., Løes IM; Department of Clinical Science, University of Bergen, and Department of Oncology, Haukeland University, Hospital, Bergen, Norway., Imai K; Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan., He J; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland., Pawlik TM; Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio., Kaczirek K; Department of General Surgery, Medical University of Vienna, Vienna, Austria., Poultsides G; Department of Surgery, Stanford University School of Medicine, Stanford, California., Lønning PE; Department of Clinical Science, University of Bergen, and Department of Oncology, Haukeland University, Hospital, Bergen, Norway., Burkhart R; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland., Endo I; Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan., Baba H; Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan., Mischinger HJ; Department of General Surgery, Medical University of Graz, Graz, Austria., Aucejo FN; Department of General Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio., Kreis ME; Department of General, Visceral and Vascular Surgery, Charite Campus Benjamin Franklin, Berlin, Germany., Wolfgang CL; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland., Weiss MJ; Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.
المصدر: Annals of surgery [Ann Surg] 2021 Jun 01; Vol. 273 (6), pp. 1165-1172.
نوع المنشور: Comparative Study; Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 0372354 Publication Model: Print Cited Medium: Internet ISSN: 1528-1140 (Electronic) Linking ISSN: 00034932 NLM ISO Abbreviation: Ann Surg Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Philadelphia, PA : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Mutation*, Colonic Neoplasms/*genetics , Colonic Neoplasms/*pathology , Liver Neoplasms/*secondary , Proto-Oncogene Proteins p21(ras)/*genetics , Rectal Neoplasms/*genetics , Rectal Neoplasms/*pathology, Aged ; Colonic Neoplasms/mortality ; Female ; Humans ; Liver Neoplasms/mortality ; Male ; Middle Aged ; Prognosis ; Rectal Neoplasms/mortality ; Retrospective Studies ; Survival Rate
مستخلص: Objective: To examine the prognostic impact of tumor laterality in colon cancer liver metastases (CLM) after stratifying by Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutational status.
Background: Although some studies have demonstrated that patients with CLM from a right sided (RS) primary cancer fare worse, others have found equivocal outcomes of patients with CLM with RS versus left-sided (LS) primary tumors. Importantly, recent evidence from unresectable metastatic CRC suggests that tumor laterality impacts prognosis only in those with wild-type tumors.
Methods: Patients with rectal or transverse colon tumors and those with unknown KRAS mutational status were excluded from analysis. The prognostic impact of RS versus LS primary CRC was determined after stratifying by KRAS mutational status.
Results: 277 patients had a RS (38.6%) and 441 (61.4%) had a LS tumor. Approximately one-third of tumors (28.1%) harbored KRAS mutations. In the entire cohort, RS was associated with worse 5-year overall survival (OS) compared with LS (39.4% vs 50.8%, P = 0.03) and remained significantly associated with worse OS in the multivariable analysis (hazard ratio 1.45, P = 0.04). In wild-type patients, a worse 5-year OS associated with a RS tumor was evident in univariable analysis (43.7% vs 55.5%, P = 0.02) and persisted in multivariable analysis (hazard ratio 1.49, P = 0.01). In contrast, among patients with KRAS mutated tumors, tumor laterality had no impact on 5-year OS, even in the univariable analysis (32.8% vs 34.0%, P = 0.38).
Conclusions: This study demonstrated, for the first time, that the prognostic impact of primary tumor side differs according to KRAS mutational status. RS tumors were associated with worse survival only in patients with wild-type tumors.
Competing Interests: The authors report no conflicts of interest.
(Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.)
References: Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and metaanalysis. JAMA Oncol 2017; 3:211–219.
Holch JW, Ricard I, Stintzing S, et al. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer 2017; 70:87–98.
Creasy JM, Sadot E, Koerkamp BG, et al. The impact of primary tumor location on long-term survival in patients undergoing hepatic resection for metastatic colon cancer. Ann Surg Oncol 2018; 25:431–438.
Dupre A, Malik HZ, Jones RP, et al. Influence of the primary tumour location in patients undergoing surgery for colorectal liver metastases. Eur J Surg Oncol 2018; 44:80–86.
Wang K, Xu D, Yan XL, et al. The impact of primary tumour location in patients undergoing hepatic resection for colorectal liver metastasis. Eur J Surg Oncol 2018; 44:771–777.
Makowiec F, Menzel M, Bronsert P, et al. Does the site of primary colorectal cancer influence the outcome after resection of isolated liver metastases? Dig Liver Dis 2018; 50:1088–1092.
Sasaki K, Andreatos N, Margonis GA, et al. The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis. J Surg Oncol 2016; 114:803–809.
Yamashita S, Brudvik KW, Kopetz SE, et al. Embryonic origin of primary colon cancer predicts pathologic response and survival in patients undergoing resection for colon cancer liver metastases. Ann Surg 2018; 267:514–520.
Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol 2017; 28:1713–1729.
Modest DP, Stintzing S, von Weikersthal LF, et al. Exploring the effect of primary tumor sidedness on therapeutic efficacy across treatment lines in patients with metastatic colorectal cancer: analysis of FIRE-3 (AIOKRK0306). Oncotarget 2017; 8:105749–105760.
Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol 2012; 30:2956–2962.
Ko S, Jo H, Yun S, et al. Comparative analysis of radiofrequency ablation and resection for resectable colorectal liver metastases. World J Gastroenterol 2014; 20:525–531.
Ito H, Are C, Gonen M, et al. Effect of postoperative morbidity on long-term survival after hepatic resection for metastatic colorectal cancer. Ann Surg 2008; 247:994–1002.
Passot G, Denbo JW, Yamashita S, et al. Is hepatectomy justified for patients with RAS mutant colorectal liver metastases? An analysis of 524 patients undergoing curative liver resection. Surgery 2017; 161:332–340.
Andreou A, Kopetz S, Maru DM, et al. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg 2012; 256:642–650.
Marques MC, HS CR, Costa WL Jr, et al. Is primary sidedness a prognostic factor in patients with resected colon cancer liver metastases (CLM)? J Surg Oncol 2018; 117:858–863.
Yoo W, Mayberry R, Bae S, et al. A study of effects of multicollinearity in the multivariable analysis. Int J Appl Sci Technol 2014; 4:9–19.
von Einem JC, Heinemann V, von Weikersthal LF, et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol 2014; 140:1607–1614.
Loupakis F, Schirripa M, Intini R, et al. Another chapter of the right versus left story: is primary tumor location a prognostic feature in RAS mutant metastatic colorectal cancer? Oncologist 2019; 24:e77–e79.
Stintzing S, Tejpar S, Gibbs P, et al. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. Eur J Cancer 2017; 84:69–80.
Margonis GA, Buettner S, Andreatos N, et al. Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer. JAMA Surg 2018; 153:e180996.
Loree JM, Pereira AAL, Lam M, et al. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin Cancer Res 2018; 24:1062–1072.
Loupakis F, Yang D, Yau L, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 2015; 107: doi: 10.1093/jnci/dju427. (PMID: 10.1093/jnci/dju427)
Vigano L, Russolillo N, Ferrero A, et al. Resection of liver metastases from colorectal mucinous adenocarcinoma: is this a different disease? Results of a case-control study. Ann Surg 2014; 260:878–884.
Jung MK, Shin US, Ki YJ, et al. Is the location of the tumor another prognostic factor for patients with colon cancer? Ann Coloproctol 2017; 33:210–218.
Chen JH, Asch SM. Machine learning and prediction in medicine – beyond the peak of inflated expectations. N Engl J Med 2017; 376:2507–2509.
Frankel TL, Vakiani E, Nathan H, et al. Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. Cancer 2017; 123:568–575.
Warschkow R, Sulz MC, Marti L, et al. Better survival in right-sided versus left-sided stage I - III colon cancer patients. BMC cancer 2016; 16:554.
Weiss JM, Pfau PR, O’Connor ES, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results – medicare data. J Clin Oncol 2011; 29:4401–4409.
Boeckx N, Koukakis R, Op de Beeck K, et al. Effect of primary tumor location on second- or later-line treatment outcomes in patients with RAS wild-type metastatic colorectal cancer and all treatment lines in patients with RAS mutations in four randomized panitumumab studies. Clin Colorectal Cancer 2018; 17:170–178.
Margonis GA, Buettner S, Andreatos N, et al. Anatomical resections improve disease-free survival in patients with KRAS-mutated colorectal liver metastases. Ann Surg 2017; 266:641–649.
Margonis GA, Sasaki K, Andreatos N, et al. KRAS mutation status dictates optimal surgical margin width in patients undergoing resection of colorectal liver metastases. Ann Surg Oncol 2017; 24:264–271.
Goffredo P, Utria AF, Beck AC, et al. The prognostic impact of KRAS mutation in patients having curative resection of synchronous colorectal liver metastases. J Gastrointest Surg 2018; doi: 10.1007/s11605-018-3978-4. (PMID: 10.1007/s11605-018-3978-4)
المشرفين على المادة: 0 (KRAS protein, human)
EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
تواريخ الأحداث: Date Created: 20190808 Date Completed: 20210812 Latest Revision: 20210812
رمز التحديث: 20240628
DOI: 10.1097/SLA.0000000000003504
PMID: 31389831
قاعدة البيانات: MEDLINE
الوصف
تدمد:1528-1140
DOI:10.1097/SLA.0000000000003504